04-02-2021 | Oncology | News | Article
Novel immune agent shows early promise in SCLC
AMG 757, a half-life extended, bispecific T-cell engager immunotherapy directed against DLL3, has demonstrated tolerability and antitumor activity in patients with previously treated small-cell lung cancer in a phase 1 trial.
02-02-2021 | Oncology | News | Article
Antibody–drug conjugates promising in advanced NSCLC
Three early-phase studies presented at the IASLC 2020 World Conference on Lung Cancer point to the potential of antibody–drug conjugates for the treatment of different populations of patients with advanced non-small-cell lung cancer.
Vial_syringe/© MarianVejcik / Getty Images / iStock, Woman in scanner/© Сергей Уланов / stock.adobe.com